Olmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis

The objective of this study is to investigate the participation of inflammatory and oxidative stress mediators and the effects on the expression of matrix metalloproteinase (MMP)-2, MMP-9, and receptor activator of NF-κB ligand (RANKL)/receptor activator of NF-κB (RANK)/osteoprotegerin (OPG) pathway...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Araújo, Aurigena Antunes, Souza, Graziene Lopes de, Souza, Tatiana Oliveira, Brito, Gerly Anne de Castro, Aragão, Karoline Sabóia, Medeiros, Caroline Addison Xavier de, Lourenço, Yriu, Alves, Maria do Socorro Costa Feitosa, Araújo Jr, Raimundo Fernandes de
Formato: article
Idioma:por
Publicado em: Springer-Verlag Berlin Heidelberg
Assuntos:
Experimental periodontal disease
Citocines
Immunohistochemical
Lipid peroxidant
Olmesartan
Endereço do item:https://repositorio.ufrn.br/jspui/handle/123456789/25416
https://doi.org/10.1007/s00210-013-0886-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
id ri-123456789-25416
record_format dspace
spelling ri-123456789-254162021-11-11T20:00:57Z Olmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis Araújo, Aurigena Antunes Souza, Graziene Lopes de Souza, Tatiana Oliveira Brito, Gerly Anne de Castro Aragão, Karoline Sabóia Medeiros, Caroline Addison Xavier de Lourenço, Yriu Alves, Maria do Socorro Costa Feitosa Araújo Jr, Raimundo Fernandes de Experimental periodontal disease Citocines Immunohistochemical Lipid peroxidant Olmesartan The objective of this study is to investigate the participation of inflammatory and oxidative stress mediators and the effects on the expression of matrix metalloproteinase (MMP)-2, MMP-9, and receptor activator of NF-κB ligand (RANKL)/receptor activator of NF-κB (RANK)/osteoprotegerin (OPG) pathway in the response to treatment with olmesartan, an angiotensin II type 1 receptor blocker. Male Wistar albino rats were randomly divided into five groups of ten rats each: (1) non-ligature with water, (2) ligature with water, (3) ligature with 1 mg/kg olmesartan, (4) ligature with 6 mg/kg olmesartan, and (5) ligature with 10 mg/kg olmesartan. All groups were treated with olmesartan or the vehicle by gavage daily for 10 days. Following the treatment course, the periodontal tissue of the animals was analyzed by histopathology and immunohistochemistry to determine the expression of cyclooxygenase-2 (COX-2), MMP-2, MMP-9, and members of the RANKL/RANK/OPG pathway and by ELISA and spectroscopic assay to determine the levels of interleukin (IL)-1β, IL-10, tumor necrosis factor (TNF)-α, myeloperoxidase (MPO), malonaldehyde (MDA), and glutathione. The concentrations of MPO and MDA were reduced in the group that received 6 mg/kg olmesartan (p < 0.05). In addition, the group that was treated with 6 mg/kg olmesartan showed a decreased level of IL-1β (p < 0.05), and all doses of olmesartan resulted in decreased levels of TNF-α. Furthermore, treatment with 6 mg/kg olmesartan led to downregulation of the expression of COX-2, MMP-2, MMP-9, RANKL, and RANK and to upregulation of the expression of OPG. These findings suggest that 6 mg/kg olmesartan reduces the inflammatory process and bone loss by downregulating MMPs and RANKL in osteoblasts and by upregulating OPG. 2018-06-16T11:36:45Z 2018-06-16T11:36:45Z 2013-06-19 article ARAÚJO, Aurigena Antunes de et al. Olmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis. Naunyn-Schmiedeberg's Archives of Pharmacology, p. 875-84, 2013. Disponível em: <https://link.springer.com/article/10.1007/s00210-013-0886-8>. Acesso em: 14 mar. 2018. 1432-1912 https://repositorio.ufrn.br/jspui/handle/123456789/25416 https://doi.org/10.1007/s00210-013-0886-8 por Acesso Aberto application/pdf Springer-Verlag Berlin Heidelberg
institution Repositório Institucional
collection RI - UFRN
language por
topic Experimental periodontal disease
Citocines
Immunohistochemical
Lipid peroxidant
Olmesartan
spellingShingle Experimental periodontal disease
Citocines
Immunohistochemical
Lipid peroxidant
Olmesartan
Araújo, Aurigena Antunes
Souza, Graziene Lopes de
Souza, Tatiana Oliveira
Brito, Gerly Anne de Castro
Aragão, Karoline Sabóia
Medeiros, Caroline Addison Xavier de
Lourenço, Yriu
Alves, Maria do Socorro Costa Feitosa
Araújo Jr, Raimundo Fernandes de
Olmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis
description The objective of this study is to investigate the participation of inflammatory and oxidative stress mediators and the effects on the expression of matrix metalloproteinase (MMP)-2, MMP-9, and receptor activator of NF-κB ligand (RANKL)/receptor activator of NF-κB (RANK)/osteoprotegerin (OPG) pathway in the response to treatment with olmesartan, an angiotensin II type 1 receptor blocker. Male Wistar albino rats were randomly divided into five groups of ten rats each: (1) non-ligature with water, (2) ligature with water, (3) ligature with 1 mg/kg olmesartan, (4) ligature with 6 mg/kg olmesartan, and (5) ligature with 10 mg/kg olmesartan. All groups were treated with olmesartan or the vehicle by gavage daily for 10 days. Following the treatment course, the periodontal tissue of the animals was analyzed by histopathology and immunohistochemistry to determine the expression of cyclooxygenase-2 (COX-2), MMP-2, MMP-9, and members of the RANKL/RANK/OPG pathway and by ELISA and spectroscopic assay to determine the levels of interleukin (IL)-1β, IL-10, tumor necrosis factor (TNF)-α, myeloperoxidase (MPO), malonaldehyde (MDA), and glutathione. The concentrations of MPO and MDA were reduced in the group that received 6 mg/kg olmesartan (p < 0.05). In addition, the group that was treated with 6 mg/kg olmesartan showed a decreased level of IL-1β (p < 0.05), and all doses of olmesartan resulted in decreased levels of TNF-α. Furthermore, treatment with 6 mg/kg olmesartan led to downregulation of the expression of COX-2, MMP-2, MMP-9, RANKL, and RANK and to upregulation of the expression of OPG. These findings suggest that 6 mg/kg olmesartan reduces the inflammatory process and bone loss by downregulating MMPs and RANKL in osteoblasts and by upregulating OPG.
format article
author Araújo, Aurigena Antunes
Souza, Graziene Lopes de
Souza, Tatiana Oliveira
Brito, Gerly Anne de Castro
Aragão, Karoline Sabóia
Medeiros, Caroline Addison Xavier de
Lourenço, Yriu
Alves, Maria do Socorro Costa Feitosa
Araújo Jr, Raimundo Fernandes de
author_facet Araújo, Aurigena Antunes
Souza, Graziene Lopes de
Souza, Tatiana Oliveira
Brito, Gerly Anne de Castro
Aragão, Karoline Sabóia
Medeiros, Caroline Addison Xavier de
Lourenço, Yriu
Alves, Maria do Socorro Costa Feitosa
Araújo Jr, Raimundo Fernandes de
author_sort Araújo, Aurigena Antunes
title Olmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis
title_short Olmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis
title_full Olmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis
title_fullStr Olmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis
title_full_unstemmed Olmesartan decreases IL-1β and TNF-α levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis
title_sort olmesartan decreases il-1β and tnf-α levels; downregulates mmp-2, mmp-9, cox-2, and rankl; and upregulates opg in experimental periodontitis
publisher Springer-Verlag Berlin Heidelberg
publishDate 2018
url https://repositorio.ufrn.br/jspui/handle/123456789/25416
https://doi.org/10.1007/s00210-013-0886-8
work_keys_str_mv AT araujoaurigenaantunes olmesartandecreasesil1bandtnfalevelsdownregulatesmmp2mmp9cox2andranklandupregulatesopginexperimentalperiodontitis
AT souzagrazienelopesde olmesartandecreasesil1bandtnfalevelsdownregulatesmmp2mmp9cox2andranklandupregulatesopginexperimentalperiodontitis
AT souzatatianaoliveira olmesartandecreasesil1bandtnfalevelsdownregulatesmmp2mmp9cox2andranklandupregulatesopginexperimentalperiodontitis
AT britogerlyannedecastro olmesartandecreasesil1bandtnfalevelsdownregulatesmmp2mmp9cox2andranklandupregulatesopginexperimentalperiodontitis
AT aragaokarolinesaboia olmesartandecreasesil1bandtnfalevelsdownregulatesmmp2mmp9cox2andranklandupregulatesopginexperimentalperiodontitis
AT medeiroscarolineaddisonxavierde olmesartandecreasesil1bandtnfalevelsdownregulatesmmp2mmp9cox2andranklandupregulatesopginexperimentalperiodontitis
AT lourencoyriu olmesartandecreasesil1bandtnfalevelsdownregulatesmmp2mmp9cox2andranklandupregulatesopginexperimentalperiodontitis
AT alvesmariadosocorrocostafeitosa olmesartandecreasesil1bandtnfalevelsdownregulatesmmp2mmp9cox2andranklandupregulatesopginexperimentalperiodontitis
AT araujojrraimundofernandesde olmesartandecreasesil1bandtnfalevelsdownregulatesmmp2mmp9cox2andranklandupregulatesopginexperimentalperiodontitis
_version_ 1773963019756240896

Registros relacionados